Evaluating survival in patients with Adult T-cell leukemia and HTLV-1 infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the survival outcomes of patients with Adult T-cell leukemia/lymphoma (ATL) and those chronically infected with the HTLV-1 virus. It consists of two cohorts: one group of ATL patients receiving various treatments and another group of HTLV-1 infected individuals without T lymphoproliferation. The study will collect and analyze clinical data to understand the impact of HTLV-1 on patient survival. The findings could provide insights into the disease progression and treatment efficacy for these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years old or older
* HTLV-1 infected
* T lymphoproliferation induced by HTLV-1 (cohort 1)
* without T lymphoproliferation induced by HTLV-1 (cohort 2)
* informed and accepted the collection of data

Exclusion Criteria

- Patients refusal of participation

Where it's running

• Hôpital Necker Enfants Malades
  Paris, France Recruiting

Study contacts

• Principal investigator: Ambroise MARCAIS, MD — Assistance Publique-Hôpitaux Paris
• Study coordinator: Ambroise MARCAIS, MD
• Email: ambroise.marcais@aphp.fr
• Phone: +33 1 44 49 46 99

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dolutegravir with or without Tenofovir for HTLV-1 infection

  This phase 2b trial tests whether dolutegravir alone or with tenofovir can lower HTLV-1 proviral load and improve related symptoms in adults with HTLV-1 infection.

  Recruiting Phase 2 Fundação Bahiana de Infectologia · Salvador, Estado de Bahia · NCT07555431

• Combining lenalidomide with standard chemotherapy for adult T-cell leukemia-lymphoma

  This study is testing if adding lenalidomide to standard chemotherapy can help adults with T-cell leukemia-lymphoma feel better and live longer.

  Recruiting at 16 sites Phase 1 National Cancer Institute (NCI) · Atlanta, Georgia and 18 other locations · NCT04301076

• Evaluating patients with HTLV-I infection and tropical spastic paraparesis

  This study is trying to understand how HTLV-I infection affects people with tropical spastic paraparesis over time by tracking their symptoms and health changes.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00001778

• Azacitidine and abatacept for relapsed or refractory T-cell lymphoma

  This study tests a combination of azacitidine and abatacept to see if it can shrink tumors in adults whose T-cell lymphoma has come back or not responded to treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07388563

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Venetoclax with azacitidine, chidamide, vindesine, and dexamethasone for newly diagnosed ETP-ALL–like leukemia

  This test tries a five-drug combination including venetoclax and azacitidine in adults 14–65 with newly diagnosed ETP-ALL–like leukemia to see if it improves remission rates and side effects.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07159620

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.